Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00399763
Status:
COMPLETED
Last Update Posted:
2015-07-08
First Post:
2006-11-13
Brief Title:
Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder
Sponsor:
Denver Health and Hospital Authority
Organization:
Denver Health and Hospital Authority
Study Overview
Official Title:
A Randomized Placebo-controlled Trial of Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder SUD
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out whether atomoxetine also called Strattera helps teenagers 12-19 with Attention Deficit Hyperactivity Disorder ADHD and drugalcohol problems
Detailed Description:
Evidence-based psychosocial treatments have recently been developed However very little data exist on the use of pharmacotherapy for adolescents SUD Substance Use Disorder One promising pharmacotherapy approach is to treat co-occuring psychiatric disorders A common co-occurring disorder in adolescent SUD is attention-deficithyperactivity disorder ADHD Fortunately new ADHD medications such as atomoxetine that do not have addictive potential are now available However all controlled studies of atomoxetine have specifically excluded teens with SUD Therefore little data exist on the safety and efficacy of the medication in this population This research project will address the important research gap with the specific aim to conduct a randomized placebo-controlled trial of atomoxetine for ADHD in teens with SUD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None